6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
Titel:
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
Auteur:
Pivot, Xavier Romieu, Gilles Debled, Marc Pierga, Jean-Yves Kerbrat, Pierre Bachelot, Thomas Lortholary, Alain Espié, Marc Fumoleau, Pierre Serin, Daniel Jacquin, Jean-Philippe Jouannaud, Christelle Rios, Maria Abadie-Lacourtoisie, Sophie Tubiana-Mathieu, Nicole Cany, Laurent Catala, Stéphanie Khayat, David Pauporté, Iris Kramar, Andrew